Table 1 Initial items on the management of IFI in ICU and the role of systemic LAMB discussed during the first project meeting
From: Role of liposomal amphotericin B in intensive care unit: an expert opinion paper
Items | Clinical setting | |
|---|---|---|
Treatment strategies | Invasive candidiasis in ICU | Invasive mold in ICU |
- Use of empirical therapy, particularly in abdominal candidiasis - Use of empirical therapy based on clinical criteria - Use of pre-emptive strategy based on colonization - Use of pre-emptive strategy based on biomarkers - Early withdrawal of antifungal treatment | - Use of empirical therapy - Use of empirical therapy based on clinical criteria | |
Microbiological considerations | - Role of biomarkers for non-albicans species | - Role of biomarkers in early diagnosis - Role of PCR in early diagnosis - Universal versus targeted use of microbiological diagnostics |
Pharmacological considerations on systemic LAMB | - Dosage - Safety - Comparison with other antifungal drugs and drug-drug interactions | |
Patient setting | - SARS-CoV-2 or influenza virus infections - patients on therapy with corticosteroids or immunomodulatory drugs - Chronic obstructive pulmonary disease - Diabetes - End-stage liver disease - Solid organ transplantation - Hematologic malignancy - Abdominal surgery | |